Investment Summary

PsyOmics  is a University of Cambridge spin-out working to improve the prevention, diagnosis and treatment of neuropsychiatric disorders.

Mental illness accounts for over 15% of the disease burden in developed countries and in England alone, mental illness costs over £51.6bn per annum.

PsyOmics aims to deliver blood based biomarker diagnostics to:

  • Rapidly diagnose key mental health disorders
  • Reduce misdiagnosis
  • Accelerate time to appropriate treatment

To deliver better patient outcomes for patients and their families and save health providers’ costs.